Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Influence of Oral Doxycycline on Wound Healing After Endonasal Endoscopic Sinus Surgery for Chronic Rhinosinusitis With and Without Nasal Polyposis: a Double-blind Randomized Placebo-controlled Trial (DOXYPOSTOP)

14. juni 2018 opdateret af: University Hospital, Ghent

Influence of Oral Doxycycline on Wound Healing After Endonasal Endoscopic Sinus Surgery for Chronic Rhinosinusitis With and Without Nasal Polyposis: a Double-blind Randomized Placebo-controlled Trial.

This is a randomized, double blind, placebo controlled, parallel group, study in patients with chronic rhinosinusitis with or without nasal polyps. The objective is to test the clinical efficacy of long-term low dose oral doxycycline on wound healing quality after endoscopic sinus surgery.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

33

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Ghent, Belgien
        • University Hospital Ghent
      • Bochum, Tyskland
        • Univ.-HNO-Klinik, St. Elisabeth Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • at least 18 years of age, of either sex and any race
  • diagnosis of chronic rhinosinusitis with or without nasal polyposis according to the EPOS guidelines research
  • Subjects should be regularly scheduled for bilateral functional endonasal endoscopic sinus surgery
  • Subjects must be in good health, free of any clinically significant disease that would interfere with the study schedule or procedures or compromise his/her safety.
  • Subjects must be willing to give informed consent and adhere to visit schedules, medication restrictions, and agree to perform daily diary entries.
  • Nonpregnant women of childbearing potential must use a medically acceptable, adequate form of birth control.

Exclusion Criteria:

  • Women must not be pregnant, breast feeding, or premenarcheal.
  • Subjects who have required oral corticosteroids within the previous four weeks prior to surgery.
  • Subjects who have required nasal corticosteroids within the previous one week prior to surgery.
  • Subjects with known allergic reaction on tetracyclines, diabetes (type 1 and 2), renal insufficiency, severe liver disease, systemic diseases affecting the nose (e.g. M. Wegener), prior surgeries of the paranasal sinuses.
  • Patients with the following diseases should be excluded :

    1. Cystic fibrosis based on positive sweat test or DNA alleles
    2. Gross immunodeficiency (congenital or acquired)
    3. congenital mucociliary problems e.g. primary ciliary dyskinesia (PCD)
    4. Non-invasive fungal balls and invasive fungal disease
    5. systemic vasculitis and granulomatous diseases
    6. Cocaine abuse
    7. Neoplasia

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Placebo komparator: placebo
during 56 days
Eksperimentel: doxycycline 100 mg
during 56 days

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Endoscopic evaluation of quality and speed of wound healing
Tidsramme: at 3 months after first drug intake
at 3 months after first drug intake
Recurrence of nasal polyps
Tidsramme: at 3 months after first drug intake
at 3 months after first drug intake
Recurrence of nasal polyps
Tidsramme: at 6 months after first drug intake
at 6 months after first drug intake

Sekundære resultatmål

Resultatmål
Tidsramme
nasal and exhaled NO
Tidsramme: at 3 months after first drug intake
at 3 months after first drug intake
nasal and exhaled NO
Tidsramme: at 6 months after first drug intake
at 6 months after first drug intake
subjective assessment of the wound healing
Tidsramme: at 3 months after first drug intake
at 3 months after first drug intake
subjective assessment of the wound healing
Tidsramme: at 6 months after first drug intake
at 6 months after first drug intake
chronic rhinosinusitis symptoms by the patients
Tidsramme: at 3 months after first drug intake
at 3 months after first drug intake
chronic rhinosinusitis symptoms by the patients
Tidsramme: at 6 months after first drug intake
at 6 months after first drug intake
Questionnaires: SNOT 22, RSOM, SF36 asthma control questionnaire
Tidsramme: at 3 months after first drug intake
at 3 months after first drug intake
Questionnaires: SNOT 22, RSOM, SF36 asthma control questionnaire
Tidsramme: at 6 months after first drug intake
at 6 months after first drug intake
inflammatory mediators in nasal fluid as well as in serum
Tidsramme: at 3 months after first drug intake
at 3 months after first drug intake
inflammatory mediators in nasal fluid as well as in serum
Tidsramme: at 6 months after first drug intake
at 6 months after first drug intake

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: Claus Bachert, MD, PhD, University Hospital Ghent, Belgium

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

22. november 2011

Primær færdiggørelse (Faktiske)

6. september 2016

Studieafslutning (Faktiske)

6. februar 2017

Datoer for studieregistrering

Først indsendt

8. september 2010

Først indsendt, der opfyldte QC-kriterier

9. september 2010

Først opslået (Skøn)

10. september 2010

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

15. juni 2018

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

14. juni 2018

Sidst verificeret

1. juni 2018

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 2010/384

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .